Lotte Biologics CEO James Park disclosed during a Bloomberg TV interview that the company is actively redirecting orders away from China. This strategic pivot reflects growing pressures on multinational corporations to diversify manufacturing and supply chains amid escalating US-China trade tensions and regulatory scrutiny. Park emphasized the move is driven by client demands for greater geographic diversification and reduced dependency on single markets.

The shift could signal broader industry trends as companies seek resilience against geopolitical risks and supply chain vulnerabilities exposed during global disruptions. Lotte Biologics is now prioritizing partnerships in alternative manufacturing hubs while maintaining core operations in China for specific products. This development may prompt competitors to accelerate similar transitions, reshaping global biologics production landscapes.